Neonatal thrombocytopenia: Causes and management

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 88, Issue 5, 2003, Pages

  Roberts, I ^a,b   Murray, N A ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; PENTOXIFYLLINE;

ARTIFICIAL VENTILATION; CLINICAL FEATURE; CLINICAL TRIAL; GESTATIONAL AGE; HUMAN; NECROTIZING ENTEROCOLITIS; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; REVIEW; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

EID: 0042261589     PISSN: 00039888     EISSN: 13592998     Source Type: Journal    
DOI: 10.1136/fn.88.5.f359     Document Type: Review

References (79)

1. Blajchman MA, Goldman M. Bacterial contamination of platelet concentrates: incidence, significance, and prevention. Semin Hematol 2001;38(suppl 11):20-6.
2. Regan F, Taylor C. Blood transfusion medicine. BMJ 2002;325:143-7.
3. Pahal G, Jauniaux E, Kinnon C, et al. Normal development of human fetal hematopoiesis between eight and seventeen weeks' gestation. Am J Obstet Gynecol 2000;183:1029-34.
4. Holmberg L, Gustavii B, Jonsson A. A prenatal study of fetal platelet count and size with application to the fetus at risk of Wiskott Aldrich syndrome. J Pediatr 1983;102:773-81.
5. Forestier F, Daffos F, Galacteros F. Haematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986;20:342-6.
6. Forestier F, Daffos F, Catherine N, et al. Developmental hematopoiesis in normal human fetal blood. Blood 1991;77:2360-3.
7. Hohlfeld P, Forestier F, Kaplan C, et al. Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings. Blood 1994;84:1851-6.
8. Burrows RF, Kelton JG. Incidentally detected thrombocytopenia in healthy mothers and their infants. N Engl J Med 1988;319:142-5.
9. Sainio S, Jarvenpaa A-S, Renlund M, et al. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol 2000;95:441-6.
10. de Moerloose P, Boehlen F, Extermann P, et al. Neonatal thrombocytopenia: incidence and characterization of maternal antiplatelet antibodies by MAIPA assay. Br J Haematol 1998;100:735-40.
11. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993;329:1463-6.
12. Uhrynowska M, Niznikowska-Marks M, Zupanska B. Neonatal and maternal thrombocytopenia: incidence and immune background. Eur J Haematol 2000;64:42-6.
13. Dreyfus M, Kaplan C, Verdy E, et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood 1997;89:4402-6.
14. Castle V, Andrew M, Kelton J, et al. Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986;108:749-55.
15. Mehta P, Rohitkumar V, Neumann L, et al. Thrombocytopenia in the high risk infant. J Pediatr 1980;97:791-4.
16. Murray NA, Roberts IAG. Circulating megakaryocytes and their progenitors in early thrombocytopenia in preterm neonates. Pediatr Res 1996;40:112-19.
17. Murray NA, Howarth LJ, McCloy MP, et al. Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit (NICU) patients. Transfus Med 2002;12:35-41.
18. Homans A. Thrombocytopenia in the neonate. Pediatr Clin North Am 1996;43:737-56.
19. Blanchette VS, Rand ML. Platelet disorders in newborn infants: diagnosis and management. Semin Perinatol 1997;21:53-62.
20. Sola MC, Del Vecchio A, Rimsza LM. Evaluation and treatment of thrombocytopenia in the neonatal intensive care unit. Clin Perinatol 2000;27:655-79.
21. Sola MC, Calhoun DA, Hutson AD, et al. Plasma thrombopoietin concentrations in thrombocytopenic and non-thrombocytopenic patients in a neonatal intensive care unit. Br J Haematol 1999;104:90-2.
22. Murray NA, Watts TL, Roberts IAG. Endogenous thrombopoietin levels and effect of recombinant human thrombopoietin on megakaryocyte precursors in term and preterm babies. Pediatr Res 1998;43:148-51.
23. Watts TL, Murray NA, Roberts IAG. Thrombopoietin has a primary role in the regulation of platelet production in preterm babies. Pediatr Res 1999;46:28-32.
24. IIIIn-oxine platelet survivals in thrombocytopenic infants. Blood 1987;70:652-6.
25. Forestier F, Hohlfeld P. Management of fetal and neonatal alloimmune thrombocytopenia. Biol Neonate 1998;74:395-401.
26. Muellar-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989;i:363-6.
27. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PIA1, Zwa) as determined by antenatal screening. Blood 1998;92:2280-7.
28. Davoren A, McParland P, Barnes CA, et al. Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases. J Clin Pathol 2002;55:289-92.
29. Glade-Bender J, McFarland JG, Kaplan C, et al. Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. J Pediatr 2001;138:862-7.
30. De Tar MW, Klohe E, Grosset A, et al. Neonatal alloimmune thrombocytopenia with HLA alloimmunization: case report with immunohematologic and placental findings. Pediatr Dev Pathol 2002;5:200-5.
31. Sasaki M, Yagihashi A, Kobayashi D, et al. Neonatal alloimmune thrombocytopenia due to anti-human leukocyte antigen antibody: a case report. Pediatr Hematol Oncol 2001;18:519-24.
32. Grainger JD, Morrell G, Yates J, et al. Neonatal alloimmune thrombocytopenia with significant HLA antibodies. Arch Dis Child Fetal Neonatal Ed 2002;86:F200-1.
33. Sharif U, Kuban K. Prenatal intracranial hemorrhage and neurologic complications in alloimmune thrombocytopenia. J Child Neurol 2001;16:838-42.
34. Jaegtvik S, Husebekk A, Aune B, et al. Neonatal alloimmune thrombocytopenia due to anti-HPA 1a antibodies: the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. Br J Obstet Gynaecol 2000;107:691-4.
35. Ouwehand WH, Smith G, Ranasinghe E. Management of severe alloimmune thrombocytopenia in the newborn. Arch Dis Child Fetal Neonatal Ed 2000;82:F173-5.
36. Radder CM, Brand A, Kanhai HH. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2001;185:683-8.
37. Kaplan C. Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev 2002;16:69-72.
38. Rothenberger S. Neonatal alloimmune thrombocytopenia. Ther Apher 2002;6:32-5.
39. Jolly MC, Letsky EA, Fisk NM. The management of fetal alloimmune thrombocytopenia. Prenat Diagn 2002;22:96-8.
40. Bussel JB. Alloimmune thrombocytopenia in the fetus and newborn. Semin Thromb Hemost 2001;27:245-52.
41. Ahya R, Turner ML, Urbaniak SJ. Fetomaternal alloimmune thrombocytopenia. Transfus Apheresis Sci 2001;25:139-45.
42. Murphy MF, Waters AH, Doughty HA, et al. Antenatal management of fetomaternal alloimmune thrombocytopenia: report of 15 affected pregnancies. Transfus Med 1994;4:281-92.
43. Overton TG, Duncan KR, Jolly M, et al. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol 2002;186:826-31.
44. Silver RM, Porter TF, Branch DW, et al. Neonatal alloimmune thrombocytopenia: antenatal management. Am J Obstet Gynecol 2000;182:1233-8.
45. Kaplan C, Murphy MF, Kroll H, et al. Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids: more questions than answers. European Working Group on FMAIT. Br J Haematol 1998;100:62-5.
46. Sainio S, Teramo K, Kekomaki R. Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia. Transfus Med 1999;9:321-30.
47. Blanchette VS, Johnson J, Rand M. The management of alloimmune neonatal thrombocytopenia. Baillieres Clin Haematol 2000;13:365-90.
48. Bussel J, Kaplan C. The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. Baillieres Clin Haematol 1998;11:391-408.
49. Ranasinghe E, Walton JD, Hurd CM, et al. Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia. Br J Haematol 2001;113:40-2.
50. Lee K, Beaujean F, Bierling P. Treatment of severe fetomaternal alloimmune thrombocytopenia with compatible frozen-thawed platelet concentrates. Br J Haematol 2002;117:482-3.
51. Bussel JB. Immune thrombocytopenia in pregnancy: autoimmune and alloimmune. J Reprod Immunol 1997;37:35-61.
52. Valat AS, Caulier MT, Devos P, et al. Relationships between severe neonatal thrombocytopenia and maternal characteristics in pregnancies associated with autoimmune thrombocytopenia. Br J Haematol 1998;103:397-401.
53. Kelton JG. Idiopathic thrombocytopenic purpura complicating pregnancy. Blood Rev 2002;16:43-6.
54. Burrows RF, Kelton JG. Low fetal risks in pregnancies associated with idiopathic thrombocytopenic purpura. Am J Obstet Gynecol 1990;163:1147-50.
55. Voak D, Cann R, Finney RD, et al. Working party: Gibson B, Hann IM, Holland B, Letsky EA, Napier JAF, de Silva M, Wardrop CAJ, Webb MSC. Guidelines for administration of blood products: transfusion of infants and neonates. Transfus Med 1994;4:63-9.
56. Roberts IAG, Murray NA. Management of thrombocytopenia in neonates. Br J Haematol 1999;105:864-70.
57. Calhoun DA, Christensen RD, Edstrom CS, et al. Consistent approaches to procedures and practices in neonatal hematology. Clin Perinatol 2000;27:733-53.
58. Amato M, Fauchere JC, Herman Jr U. Coagulation abnormalities in low birth weight infants with peri-intraventricular hemorrhage. Neuropediatrics 1988;19:154-7.
59. Andrew M, Castle V, Saigal S, et al. Clinical impact of neonatal thrombocytopenia. J Pediatr 1987;110:457-64.
60. Van De Bor M, Briet E, Van Bel F, et al. Hemostasis and periventricular-intraventricular hemorrhage of the newborn. American Journal of Diseases of Children 1986;140:1131-4.
61. Andrew M, Vegh P, Caco VC, et al. A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. J Pediatr 1993;123:285-91.
62. Carr R, Modi N, Dare CJ, et al. A randomized, controlled trial of prophylactic granulocyte-macrophage colony-stimulating factor in human newborns less than 32 weeks gestation. Pediatrics 1999;103:796-802.
63. Haque KN. Intravenous immunoglobulins versus sepsis. Pediatrics 2000;105:1173.
64. Lauterboch R, Pawlik D, Kowalczyk D, et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999;27:807-14.
65. Fagbemi AO, Wright N, Lakhoo K, et al. Immunoreactive epidermal growth factor receptors are present in gastrointestinal epithelial cells of preterm infants with necrotising enterocolitis. Early Hum Dev 2001;65:1-9.
66. Albert TSE, Meng G, Simms P, et al. Thrombopoietin in the thrombocytopenic term and preterm newborn. Pediatrics 2000;105:1286-91.
67. Nishihira H, Toyoda Y, Miyazaki H, et al. Growth of macroscopic human megakaryocyte colonies from cord blood with recombinant human thrombopoietin (c-mpl ligand) and the effects of gestational age on the frequency of colonies. Br J Haematol 1996;92:23-8.
68. Sola MC, Du Y, Hutson AD, et al. Dose-response relationship of megakaryocyte progenitors from bone marrow and peripheral blood of thrombocytopenic neonates to recombinant thrombopoietin [abstract]. Pediatr Res 1999;45:153A.
69. Watts TL, Murray NA, Roberts IAG. Thrombopoietin in term and preterm babies with and without thrombocytopenia [abstract]. Blood 1997;90:141a.
70. Sola MC, Christensen RD, Hutson AD, et al. Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys. Pediatr Res 2000;47:208-14.
71. Schwertschlag US, Trepicchio WL, Dykstra KH, et al. Hemopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 1999;13:1307-15.
72. Chang M, Williams A, Ishizawa L, et al. Endogenous interleukin-11 (IL-11) expression is increased and prophylactic use of exogenous IL-11 enhances platelet recovery and improves survival during thrombocytopenia associated with experimental group B sepsis in neonatal rats. Blood Cells Mol Dis 1996;22:57-67.
73. Opal SM, Jhung JW, Keith JC Jr, et al. Recombinant human interleukin-11 in experimental pseudomonas aeruginosa sepsis in immunocompromised animals. J Infect Dis 1998;178:1205-8.
74. Opal SM, Jhung JW, Keith JC Jr, et al. Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis. Blood 1999;93:3467-72.
75. Claud E, Jackson M, Jilling T, et al. Interleukin-11 diminishes intestinal injury in a rat model of necrotizing enterocolitis [abstract]. Pediatr Res 2000;47:163A.
76. McCloy MP, Howarth U, Watts TL, et al. The role of IL-11 in neonatal thrombocytopenia. Hematol J 2000;1(suppl 1 ):139.
77. McCloy MP, Howarth U, Watts TL, et al. The rote of IL-11 in neonatal thrombocytopenia [abstract]. Blood 2000;96(suppl 1):564a.
78. McCloy MP, Roberts IAG, Howarth U, et al. IL-11 levels in healthy and thrombocytopenic neonates: potential for IL-11 therapy in sepsis- and NEC-related thrombocytopenia in preterm neonates. Pediatr Res 2002;51:756-60.
79. Roberts IAG, Murray NA. Thrombocytopenia in the newborn. In: Michelson A, ed. The platelets. New York: Elsevier Science, 2002:635-8.